CCR5 and metabolic dysfunction-associated steatohepatitis: Cenicriviroc is a dual CCR-2 and CCR-5 antagonist under investigation as a putative therapy for NASH.54 Recently, year 1 primary analysis of the 2-year CENTAUR study demonstrated that cenicriviroc had an antifibrotic effect without impacting on degree or inducing regression of steatohepatitis.